Published in Am Heart J on November 01, 2005
Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab (2007) 9.77
Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s. J Am Coll Cardiol (2008) 3.36
Carotid intimal medial thickness in human immunodeficiency virus-infected women: effects of protease inhibitor use, cardiac risk factors, and the metabolic syndrome. J Clin Endocrinol Metab (2006) 1.67
Cardiovascular implications from untreated human immunodeficiency virus infection. Eur Heart J (2011) 1.64
The roles of HIV-1 proteins and antiretroviral drug therapy in HIV-1-associated endothelial dysfunction. J Investig Med (2008) 1.14
Cardiovascular disease in HIV infection. Curr Opin HIV AIDS (2011) 1.08
No impairment of endothelial function or insulin sensitivity with 4 weeks of the HIV protease inhibitors atazanavir or lopinavir-ritonavir in healthy subjects without HIV infection: a placebo-controlled trial. Clin Infect Dis (2008) 1.06
The consequences of HIV infection and antiretroviral therapy use for cardiovascular disease risk: shifting paradigms. Curr Opin HIV AIDS (2009) 0.96
Hypertriglyceridemia, Metabolic Syndrome, and Cardiovascular Disease in HIV-Infected Patients: Effects of Antiretroviral Therapy and Adipose Tissue Distribution. Int J Vasc Med (2011) 0.95
Lipoprotein Changes in HIV-Infected Antiretroviral-Naïve Individuals after Starting Antiretroviral Therapy: ACTG Study A5152s Stein: Lipoprotein Changes on Antiretroviral Therapy. J Clin Lipidol (2008) 0.94
Pharmacokinetic and metabolic effects of American ginseng (Panax quinquefolius) in healthy volunteers receiving the HIV protease inhibitor indinavir. BMC Complement Altern Med (2008) 0.93
Proteinuria and endothelial dysfunction in stable HIV-infected patients. A pilot study. J Acquir Immune Defic Syndr (2007) 0.91
Inhibition of bilirubin metabolism induces moderate hyperbilirubinemia and attenuates ANG II-dependent hypertension in mice. Am J Physiol Regul Integr Comp Physiol (2009) 0.91
Insulin resistance predicts endothelial dysfunction and cardiovascular risk in HIV-infected persons on long-term highly active antiretroviral therapy. AIDS (2008) 0.91
Relationship of body composition, metabolic status, antiretroviral use, and HIV disease factors to endothelial dysfunction in HIV-infected subjects. AIDS Res Hum Retroviruses (2010) 0.89
Severe impairment of endothelial function with the HIV-1 protease inhibitor indinavir is not mediated by insulin resistance in healthy subjects. Cardiovasc Toxicol (2008) 0.89
Endothelial dysfunction, arterial stiffening, and intima-media thickening in large arteries from HIV-1 transgenic mice. Ann Biomed Eng (2012) 0.83
Modeling of human prokineticin receptors: interactions with novel small-molecule binders and potential off-target drugs. PLoS One (2011) 0.83
HIV-1, reactive oxygen species, and vascular complications. Free Radic Biol Med (2012) 0.83
Current Efavirenz (EFV) or ritonavir-boosted lopinavir (LPV/r) use correlates with elevate markers of atherosclerosis in HIV-infected subjects in Addis Ababa, Ethiopia. PLoS One (2015) 0.81
Azidothymidine (AZT) leads to arterial stiffening and intima-media thickening in mice. J Biomech (2013) 0.81
Influence of immune activation and inflammatory response on cardiovascular risk associated with the human immunodeficiency virus. Vasc Health Risk Manag (2015) 0.81
Switching antiretroviral therapy to minimize metabolic complications. HIV Ther (2010) 0.80
Endothelial, inflammatory, coagulation, metabolic effects and safety of etravirine in HIV-uninfected volunteers. AIDS Patient Care STDS (2011) 0.80
Microvascular Endothelial Dysfunction and Enhanced Thromboxane and Endothelial Contractility in Patients with HIV. J AIDS Clin Res (2013) 0.79
Antiretrovirals induce endothelial dysfunction via an oxidant-dependent pathway and promote neointimal hyperplasia. Toxicol Sci (2010) 0.79
Coronary and peripheral endothelial function in HIV patients studied with positron emission tomography and flow-mediated dilation: relation to hypercholesterolemia. Eur J Nucl Med Mol Imaging (2008) 0.78
Mitochondrial DNA variation and changes in adiponectin and endothelial function in HIV-infected adults after antiretroviral therapy initiation. AIDS Res Hum Retroviruses (2013) 0.77
HIV Infection and Acute Stroke: A Case Report and a Review of the Literature. Case Rep Med (2013) 0.75
Understanding the complications of antiretroviral drugs. Clin Infect Dis (2008) 0.75
Changes in Cardiovascular Disease Risk Factors With Immediate Versus Deferred Antiretroviral Therapy Initiation Among HIV-Positive Participants in the START (Strategic Timing of Antiretroviral Treatment) Trial. J Am Heart Assoc (2017) 0.75
Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med (2003) 4.57
The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther (2003) 3.71
Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s. J Am Coll Cardiol (2008) 3.36
Biological stress response terminology: Integrating the concepts of adaptive response and preconditioning stress within a hormetic dose-response framework. Toxicol Appl Pharmacol (2007) 2.37
State of the science conference: Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary. Circulation (2008) 2.17
Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J Acquir Immune Defic Syndr (2002) 1.98
Nutritional model of steatohepatitis and metabolic syndrome in the Ossabaw miniature swine. Hepatology (2009) 1.78
Role of the Kupffer cell in mediating hepatic toxicity and carcinogenesis. Toxicol Sci (2006) 1.75
Screening for coronary artery disease in patients with diabetes. Diabetes Care (2007) 1.72
Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis. Hepatology (2003) 1.65
Women and heart disease: the role of diabetes and hyperglycemia. Arch Intern Med (2004) 1.63
Hepatic effects of 2-butoxyethanol in rodents. Toxicol Sci (2002) 1.53
Acute insulin response and beta-cell compensation in normal subjects treated with olanzapine or risperidone for 2 weeks. Diabetes Care (2007) 1.45
Endothelin contributes to basal vascular tone and endothelial dysfunction in human obesity and type 2 diabetes. Diabetes (2002) 1.35
Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo. J Clin Endocrinol Metab (2002) 1.30
Stochastic prediction of CYP3A-mediated inhibition of midazolam clearance by ketoconazole. Drug Metab Dispos (2006) 1.27
Effects of HIV infection and antiretroviral therapy on the heart and vasculature. Circulation (2008) 1.25
Conditional beta-catenin loss in mice promotes chemical hepatocarcinogenesis: role of oxidative stress and platelet-derived growth factor receptor alpha/phosphoinositide 3-kinase signaling. Hepatology (2010) 1.23
Ultrasonographic measures of cardiovascular disease risk in antiretroviral treatment-naive individuals with HIV infection. AIDS (2013) 1.23
Effects of HIV protease inhibitor ritonavir on Akt-regulated cell proliferation in breast cancer. Clin Cancer Res (2006) 1.23
Insulin resistance in the vasculature. J Clin Invest (2013) 1.16
Adipose tissue production of hepatocyte growth factor contributes to elevated serum HGF in obesity. Am J Physiol Endocrinol Metab (2006) 1.16
Interactions between endothelin and nitric oxide in the regulation of vascular tone in obesity and diabetes. Diabetes (2004) 1.12
Mixed patterns of changes in central and peripheral fat following initiation of antiretroviral therapy in a randomized trial. J Acquir Immune Defic Syndr (2006) 1.12
Physiologically based pharmacokinetic model of mechanism-based inhibition of CYP3A by clarithromycin. Drug Metab Dispos (2009) 1.11
Improvement in HIV-related endothelial dysfunction using the anti-inflammatory agent salsalate: a pilot study. AIDS (2008) 1.11
The interaction between St John's wort and an oral contraceptive. Clin Pharmacol Ther (2003) 1.10
Re: Waalkes et al.: Lung tumors in mice induced by "whole-life" inorganic arsenic exposure at human-relevant doses, Arch Toxicol, 2014. Arch Toxicol (2014) 1.08
Linear low-dose extrapolation for noncancer heath effects is the exception, not the rule. Crit Rev Toxicol (2011) 1.07
The effects of highly active antiretroviral therapy on albuminuria in HIV-infected persons: results from a randomized trial. Nephrol Dial Transplant (2005) 1.06
Evaluating uncertainty to strengthen epidemiologic data for use in human health risk assessments. Environ Health Perspect (2014) 1.06
Body composition, soluble markers of inflammation, and bone mineral density in antiretroviral therapy-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr (2013) 1.05
Worsening endothelial function with efavirenz compared to protease inhibitors: a 12-month prospective study. PLoS One (2012) 1.04
Inflammation and complications of HIV disease. J Infect Dis (2010) 1.04
The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates. Clin Pharmacol Ther (2006) 1.02
Effects of switching from efavirenz to raltegravir on endothelial function, bone mineral metabolism, inflammation, and renal function: a randomized, controlled trial. J Acquir Immune Defic Syndr (2013) 1.02
Clinical aspects of endothelial dysfunction associated with human immunodeficiency virus infection and antiretroviral agents. Cardiovasc Toxicol (2004) 1.01
Effect of transport stress on respiratory disease, serum antioxidant status, and serum concentrations of lipid peroxidation biomarkers in beef cattle. Am J Vet Res (2004) 1.00
Inhibition of human intestinal wall metabolism by macrolide antibiotics: effect of clarithromycin on cytochrome P450 3A4/5 activity and expression. Clin Pharmacol Ther (2005) 0.99
Semiphysiologically based pharmacokinetic models for the inhibition of midazolam clearance by diltiazem and its major metabolite. Drug Metab Dispos (2009) 0.99
Hemangiosarcoma in rodents: mode-of-action evaluation and human relevance. Toxicol Sci (2009) 0.98
Pentoxifylline, inflammation, and endothelial function in HIV-infected persons: a randomized, placebo-controlled trial. PLoS One (2013) 0.98
Alterations in brain structure and function in breast cancer survivors: effect of post-chemotherapy interval and relation to oxidative DNA damage. Breast Cancer Res Treat (2012) 0.97
Mode of action in relevance of rodent liver tumors to human cancer risk. Toxicol Sci (2005) 0.96
Lipoprotein Changes in HIV-Infected Antiretroviral-Naïve Individuals after Starting Antiretroviral Therapy: ACTG Study A5152s Stein: Lipoprotein Changes on Antiretroviral Therapy. J Clin Lipidol (2008) 0.94
Mode of action framework analysis for receptor-mediated toxicity: The peroxisome proliferator-activated receptor alpha (PPARα) as a case study. Crit Rev Toxicol (2013) 0.93
The human relevance of information on carcinogenic modes of action: overview. Crit Rev Toxicol (2003) 0.93
Changes in thrombolytic and inflammatory markers after initiation of indinavir- or amprenavir-based antiretroviral therapy. Cardiovasc Toxicol (2004) 0.91
Developing high-throughput HIV incidence assay with pyrosequencing platform. J Virol (2013) 0.91
Relationship between microbial translocation and endothelial function in HIV infected patients. PLoS One (2012) 0.91
Proteinuria and endothelial dysfunction in stable HIV-infected patients. A pilot study. J Acquir Immune Defic Syndr (2007) 0.91
Anti-inflammatory treatment with pentoxifylline improves HIV-related endothelial dysfunction: a pilot study. AIDS (2010) 0.90
FFAs: do they play a role in vascular disease in the insulin resistance syndrome? Curr Diab Rep (2005) 0.89
Effect of oral methyl-t-butyl ether (MTBE) on the male mouse reproductive tract and oxidative stress in liver. Reprod Toxicol (2008) 0.88
Induction of multidrug resistance-1 and cytochrome P450 mRNAs in human mononuclear cells by rifampin. Drug Metab Dispos (2002) 0.88
Activity of CYP2E1 and CYP3A enzymes in adults with moderate alcohol consumption: a comparison with nonalcoholics. Hepatology (2005) 0.87
The effects of an oral contraceptive containing ethinyloestradiol and norgestrel on CYP3A activity. Br J Clin Pharmacol (2002) 0.87
Comparative effects of phthalate monoesters on gap junctional intercellular communication and peroxisome proliferation in rodent and primate hepatocytes. J Toxicol Environ Health A (2002) 0.86
Troglitazone therapy improves endothelial function to near normal levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab (2003) 0.86
Acrylonitrile-induced oxidative stress and oxidative DNA damage in male Sprague-Dawley rats. Toxicol Sci (2009) 0.85
Proposed mode of action of benzene-induced leukemia: Interpreting available data and identifying critical data gaps for risk assessment. Chem Biol Interact (2010) 0.85
Dextromethorphan to dextrorphan urinary metabolic ratio does not reflect dextromethorphan oral clearance. Drug Metab Dispos (2005) 0.85
Insulin sensitivity is preserved despite disrupted endothelial function. Am J Physiol Endocrinol Metab (2006) 0.85
Dose-related induction of hepatic preneoplastic lesions by diethylnitrosamine in C57BL/6 mice. Toxicol Pathol (2011) 0.84
Oxidative stress in chronic liver disease: relationship between peripheral and hepatic measurements. Am J Med Sci (2011) 0.84
Neither proteinuria nor albuminuria is associated with endothelial dysfunction in HIV-infected patients without diabetes or hypertension. J Infect Dis (2011) 0.84
Subchronic acrylamide treatment induces a tissue-specific increase in DNA synthesis in the rat. Toxicol Lett (2004) 0.83
Mechanisms for the induction of oxidative stress in Syrian hamster embryo cells by acrylonitrile. Toxicol Sci (2002) 0.83
Exogenous cushing syndrome mimicking human immunodeficiency virus lipodystrophy. Clin Infect Dis (2002) 0.83
Interaction between midazolam and clarithromycin in the elderly. Br J Clin Pharmacol (2007) 0.83
Effect of cirrhosis and liver transplantation on the gender difference in QT interval. Am J Cardiol (2005) 0.83
Rate of onset of inhibition of gut-wall and hepatic CYP3A by clarithromycin. Eur J Clin Pharmacol (2012) 0.82
Mechanisms of 2-butoxyethanol-induced hemangiosarcomas. Toxicol Sci (2006) 0.82
Indicators of oxidative stress and apoptosis in mouse whole lung and Clara cells following exposure to styrene and its metabolites. Toxicology (2009) 0.82
Acrylonitrile-induced oxidative DNA damage in rat astrocytes. Environ Mol Mutagen (2006) 0.81
Weight loss and vascular function: the good and the unknown. Hypertension (2008) 0.81
Minocycline blocks 6-hydroxydopamine-induced neurotoxicity and free radical production in rat cerebellar granule neurons. Life Sci (2003) 0.81
Obesity and endothelial dysfunction. Semin Vasc Med (2005) 0.81
Effect of different obesogenic diets on pancreatic histology in Ossabaw miniature swine. Pancreas (2011) 0.80
L-carnitine may attenuate free fatty acid-induced endothelial dysfunction. Ann N Y Acad Sci (2004) 0.80
Role of amylin in insulin secretion and action in humans: antagonist studies across the spectrum of insulin sensitivity. Diabetes Metab Res Rev (2002) 0.79
Effects of 2-butoxyethanol on hepatic oxidative damage. Toxicol Lett (2002) 0.79
Microbial translocation and metabolic and body composition measures in treated and untreated HIV infection. AIDS Res Hum Retroviruses (2013) 0.79
Intramuscular haloperidol or lorazepam and QT intervals in schizophrenia. J Clin Pharmacol (2004) 0.78
Species differences in the induction of hepatocellular DNA synthesis by diethanolamine. Toxicol Sci (2005) 0.78
Morphological transformation and oxidative stress induced by cyanide in Syrian hamster embryo (SHE) cells. Toxicol Sci (2002) 0.77
Oxidative status in neuroblastoma: a source of stress? J Pediatr Surg (2008) 0.77
Weight loss and endothelial function in obesity. Diabetes Care (2003) 0.77
Evaluation of partial area under the concentration time curve to estimate midazolam apparent oral clearance for cytochrome P450 3A phenotyping. Drug Metabol Drug Interact (2013) 0.77
Effects of commonly administered agents and genetics on nebivolol pharmacokinetics: drug-drug interaction studies. J Clin Pharmacol (2010) 0.77
Furosemide responsiveness, non-adherence and resistance during the chronic treatment of heart failure: a longitudinal study. Br J Clin Pharmacol (2004) 0.76
Mechanisms of 2-butoxyethanol carcinogenicity: studies on Syrian Hamster Embryo (SHE) cell transformation. Toxicol Sci (2002) 0.76
Kupffer cells participate in 2-butoxyethanol-induced liver hemangiosarcomas. Toxicology (2010) 0.76
HIV-associated lipoatrophy: what are the kinder, gentler agents? Clin Infect Dis (2005) 0.76
Acrylamide-induced cellular transformation. Toxicol Sci (2002) 0.76
Depletion of Kupffer cells modulates ethanol-induced hepatocyte DNA synthesis in C57Bl/6 mice. Environ Toxicol (2012) 0.76
Constitutional polymorphisms of prostate cancer: prognostic and diagnostic implications. Future Oncol (2007) 0.76
Assessment of possible carcinogenicity of oxyfluorfen to humans using mode of action analysis of rodent liver effects. Toxicol Sci (2012) 0.76
PPARalpha and effects of TCE. Environ Health Perspect (2007) 0.75